投資概要
公司公佈半年報業績，醫藥工業和零售保持快速增長，醫藥商業在兩票制影響下依然 保持雙位數的增長。盈利能力持續向好，利潤率提升。預計下半年流通業務將進一步 改善，維持我們的每股收益預測。考慮到人民幣貶值影響，我們調整目標價至24港 元。(現價截至9月10日)
Graduated from Hong Kong Polytechnic University, Master of Finance (Investment Management). Possess bachelor degree majoring in Financial Management from Southwestern University of Finance and Economics. Focus on industry prospect and corporate fundamentals to explore investment value and cover pharmaceutical and consumer industry.
